3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Nasopharyngeal Carcinoma
4
Rectal Neoplasms
2
Melanoma
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Squamous Cell Non-small Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Recurrence
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Nasopharyngeal Neoplasms
1
Locally Advanced Low Rectal Adenocarcinoma
1
HER2+ Breast Cancer
1
Epstein-Barr Virus Infections
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Colorectal Neoplasms
1
Interventions
Dacarbazine
4
pembrolizumab
3
binimetinib
3
Nivolumab
3
encorafenib
2
cemiplimab
2
Sirolimus
2
Ipilimumab
2
vitespin
1
trametinib
1
tilsotolimod
1
spartalizumab
1
oblimersen
1
linrodostat
1
lifileucel
1
gp100 Melanoma Antigen
1
dabrafenib
1
bempegaldesleukin
1
aldesleukin
1
Vinblastine
1
Vemurafenib
1
Tretinoin
1
Tacrolimus
1
Standard of Care
1
Sodium Chloride
1
Radiotherapy
1
Radiation
1
Interleukin-2
1
Interferon-alpha
1
Interferon alpha-2
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Skin Neoplasms
×
spartalizumab
×
Clear all
NCT02967692
2025-09-18
COMBI-i
Novartis
Phase 3
Terminated
568 enrolled
28 charts